Comparison Between hCG and GnRH Agonist for Ovulation Induction in Patients With High Response to IVF Drugs
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00415792|
Recruitment Status : Unknown
Verified January 2007 by Eugonia.
Recruitment status was: Active, not recruiting
First Posted : December 25, 2006
Last Update Posted : January 5, 2007
|Condition or disease||Intervention/treatment||Phase|
|Infertility||Drug: Arvekap, Pregnyl||Phase 4|
hCG is commonly used for the substitution of the endogenous LH surge to induce oocyte maturation and ovulation induction in ovarian hyperstimulation protocols for in vitro fertilization (IVF). However, hCG is related to the occurrence of the ovarian hyperstimulation syndrome (OHSS), a potentially life-threatening complication and hyper-responding patients are particularly in high risk. An alternative to exogenous hCG is the administration of a GnRH agonist inducing an endogenous rise in both LH and FSH levels due to the initial flare effect.
Comparisons: Pregnancy rates and embryological data will be compared from hyper-responding patients receiving either GnRH agonist (Arvekap) or hCG (Pregnyl) for ovulatrion induction following a GnRH antagonist treatment cycle.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Administration of Human Chorionic Gonadotropin (hCG) Versus Gonadotropin Releasing Hormone (GnRH) Agonist for Ovulation Induction in Hyper-Responder Patients|
|Study Start Date :||November 2003|
|Study Completion Date :||July 2005|
- Ongoing pregnancy per embryo transfer
- Biochemical pregnancy per embryo transfer
- Clinical pregnancy per embryo transfer
- Embryological data
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00415792
|Athens, Greece, 11528|
|Principal Investigator:||Tryfon Lainas, PhD||Eugonia|